Cappucci Stefanie P, Smith Wade S, Schwartzstein Richard, White Douglas B, Mitchell Susan L, Fehnel Corey R
Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Neurohospitalist. 2023 Jan;13(1):61-68. doi: 10.1177/19418744221123194. Epub 2022 Oct 9.
Donation after circulatory death (DCD) is becoming increasingly common, yet little is known about the way potential donors receive end-of-life care.
The aims of this systematic review are to describe the current practice in end-of-life care for potential donors and identify metrics that are being used to assess discomfort among these patients.
This review encompasses published literature between June 1, 2000 and June 31, 2020 of end-of-life care received by potential DCD patients. The population of interest was defined as patients eligible for Maastracht classification III donation after circulatory death for a solid organ transplantation. Outcomes examined included: analgesic or palliative protocols, and surrogates of discomfort (eg dyspnea, agitation).
Among 141 unique articles, 27 studies were included for full review. The primary reason for exclusion was lack of protocol description, or lack of reporting on analgesic medications. No primary research studies specifically examined distress in the DCD eligible population. Numerous professional guidelines were identified. Surveys of critical care practitioners identified concerns regarding the impact of symptom management on hastening the dying process in the DCD population as a potential barrier to end-of-life palliative treatment.
There is a paucity of empirical evidence for end-of-life symptom assessment and management for DCD patients. Key evidence gaps identified for DCD include the need for: i) a multidisciplinary structure of treatment teams and preferred environment for DCD, ii) objective tools for monitoring of distress in this patient population, and iii) evidence guiding the administration of analgesic medications following withdrawal of life sustaining therapy.
循环性死亡后器官捐献(DCD)越来越普遍,但对于潜在捐献者接受临终关怀的方式却知之甚少。
本系统评价的目的是描述潜在捐献者临终关怀的当前实践,并确定用于评估这些患者不适程度的指标。
本评价涵盖了2000年6月1日至2020年6月31日期间发表的关于潜在DCD患者接受临终关怀的文献。研究对象定义为符合马斯特里赫特分类III级、可进行实体器官移植的循环性死亡后器官捐献的患者。所考察的结果包括:镇痛或姑息治疗方案,以及不适的替代指标(如呼吸困难、烦躁不安)。
在141篇独立文章中,27项研究被纳入全面评价。排除的主要原因是缺乏方案描述或未报告镇痛药物使用情况。没有原发性研究专门考察符合DCD条件人群的痛苦状况。确定了许多专业指南。对重症监护从业者的调查发现,他们担心症状管理对加速DCD人群死亡过程的影响,这是临终姑息治疗的一个潜在障碍。
关于DCD患者临终症状评估和管理的实证证据匮乏。DCD确定的关键证据空白包括:i)治疗团队的多学科结构和DCD的理想环境,ii)监测该患者人群痛苦状况的客观工具,以及iii)指导撤除维持生命治疗后镇痛药物使用的证据。